CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lipigon Pharmaceuticals AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lipigon Pharmaceuticals AB
Tvistevagen 48 C
UMEA, 907 36  Sweden Ticker: LPGOLPGO
Business Summary
Lipigon Pharmaceuticals AB is a Sweden-based project portfolio company. Lipigon's business concept is to develop medicines with new, unique mechanisms of action (so-called first-in-class) for diseases that lack adequate treatment. The Company develops medicines with a focus on diseases where the body's ability to handle fats is disturbed, so-called lipid-related diseases, and where there are unmet medical needs. Initially, the Company's development focuses on advanced diseases or genetically defined patient segments where it is possible to identify treatment effects early in the clinical development. It creates the conditions for studies with fewer patients and a shorter path to market approval and thus a reduced development risk.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

General Information
Outstanding Shares: 148,330,518 (As of 6/30/2024)
Stock Exchange: STO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024